

#### Proceedings Article

# Brownian superparamagnetic nanoparticles for cell viability assessment in Magnetic Particle Imaging

Renesmee Kuo <sup>@[a](https://orcid.org/0000-0002-9309-2914),c,</sup>\*• Chinmoy Saayujya <sup>[b](https://orcid.org/0000-0002-6725-3999)</sup> Kim Hwang Yeo<sup>a</sup> Quincy Huynh <sup>®b</sup> Ir[a](https://orcid.org/0000-0002-3310-6085)ti Rodrigo <sup>na</sup>. Prashant Chandrasekharan na Steven Conolly na,*b* 

*<sup>a</sup>*Department of Bioengineering, University of California, Berkeley, California, USA

*<sup>b</sup>* Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, California, USA

*<sup>c</sup>* Department of Electrical Engineering, Stanford University, California, USA

<sup>∗</sup>Corresponding author, email: [renesmeek@berkeley.edu](mailto:renesmeek@berkeley.edu)

© 2023 Kuo et al.; licensee Infinite Science Publishing GmbH

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### Abstract

Molecular imaging tools can noninvasively track cells *in vivo*. However, no techniques today can rapidly monitor cell therapies to allow for nimble treatment optimization for each patient, the epitome of Personalized Medicine. Magnetic Particle Imaging (MPI) is a new tracer imaging technology that could soon provide MDs unequivocal therapy treatment feedback in just three days. MPI with Brownian superparamagnetic iron oxide nanoparticles shows promise towards noninvasive sensing of cell viability via viscosity changes in apoptotic cells. This unique ability could greatly improve the efficacy of cell therapies by enabling rapid personalization of the treatment.

# I. Introduction

There are now over 1,000 cell therapies in clinical trials. Current molecular imaging methods, including MRI with 19F or superparamagnetic iron oxide (SPIO), ultrasound with microbubbles and nuclear medicine with radioisotopes, all have limitations in persistence, sensitivity, resolution or artifacts. No cell tracking tools today can fully and rapidly assess treatment efficacy to allow for nimble treatment optimization for each patient. For example, immunotherapy has become a mainstream treatment of bloodborne cancers (10% of all tumors), but it remains an open challenge for "solid tumors," which account for 90% of tumors [[2](#page-2-0)]. Magnetic Particle Imaging (MPI) is a new imaging method ideal for tracking cells [[1,](#page-2-1) [3](#page-2-2)[–8](#page-2-3)]. It could soon allow MDs to gauge treatment efficacy directly and rapidly—in just three days. MPI offers ideal micromolar sensitivity; positive, linear and quantitative

contrast with 100-fold higher SNR/cell compared to 19F MRI; zero radiation, robust penetration and no artifacts anywhere in the body—including in the lungs and inside bones (Fig. [1\)](#page-1-0).

An outstanding challenge for all cell tracking methods is distinguishing live from apoptotic cells. Cellular viscosity changes when cells undergo apoptosis [[9](#page-2-4)]. While some imaging techniques could potentially discern cell viability through genetic manipulation, they are often not translational.

MPI, in contrast, provides a unique sensing ability that could detect cell viability. MPI scanning requires an 180-degree rotation of the SPIO. This rotation time is slowed by Néelian and Brownian relaxation constants (Fig. [2\)](#page-1-1) [[10](#page-2-5)]. Néelian and Brownian relaxation in MPI is akin to T1 and T2 in MRI. In Néelian relaxation, the SPIO domain flips with no physical rotation, so Néelian SPIOs cannot sense viscosity changes. With Brownian

<span id="page-1-0"></span>

Figure 1: **UC Berkeley first-in-animal study** of MPI directly monitoring cell therapy quickly in 3 days, allowing time for modifying the therapy. Here, MPI can see 1 million therapeutic cells in lungs (Day 1) and in the liver (Day 12) (Reproduced with permission from Springer Nature) [[1](#page-2-1)].

relaxation, the entire SPIO aligns with the field, so Brownian relaxation scales linearly with the nanoscale viscosity. Since Néelian and Brownian relaxation occurs in parallel, we observe the faster of the two. Here, we demonstrate for the first time promising data showing that Brownian MPI particles can infer cell death via viscosity sensing.

<span id="page-1-1"></span>

Figure 2: **SPIO relaxation mechanisms** Brownian relaxation (left) involves the physical rotation of the SPIO, including its shell and any attached ligands, with the applied magnetic field. Néelian relaxation (right) only involves the reorientation of the internal magnetic domain of the SPIO with the applied magnetic field. There is no physical rotation of the SPIO.

### II. Methods

We used nanoComposix NanoXact (hydrodynamic diameter 16 nm, PVP coating) and Magnetic Insight VivoTrax (hydrodynamic diameter 4.2, carboxydextran coating) to label LLC1 lung cancer cells. NanoXact was chosen for our Brownian SPIO because we found its relaxation time scales linearly with viscosity [[11](#page-2-6)]. VivoTrax was chosen as

<span id="page-1-2"></span>

Figure 3: **MPI can noninvasively gauge cell viability** Cellular viscosity changes when cells undergo apoptosis. MPI viscometry can infer cell death (p<0.01) of therapeutic cells. No other imaging modality can provide this unique sensing capability.

our Néelian SPIO as its relaxation time does not vary with viscosity. Due to concentration variations, two flasks of cells were incubated with 100 µL of NanoXact and the other two with 300 µL of VivoTrax. After 24 hours, the cells were harvested and washed with a phosphate buffer. The NanoXact and VivoTrax labeled cells were divided into two groups. One group was incubated at 37◦C (control), and the other group was incubated in a hot water bath at 60◦C to induce cell death via hyperthermia for 2 hours [[12](#page-2-7)]. Relaxation time constants of both groups of cells were measured using a periodic square-wave pulsed magnetic field of amplitude 10 mT and 1 kHz frequency in the Arbitrary Waveform Relaxometer (AWR) [[13](#page-2-8)]. We integrated and fitted the gradiometric received signals to a rising exponential function to determine the relaxation time constant.

#### III. Results and Discussion

We observed distinct relaxation mechanisms in the two groups of cells labeled with Brownian (NanoXact) and Néelian (VivoTrax) SPIOs (Fig. [3\)](#page-1-2). As hypothesized, there are statistically significant  $(p<0.01)$  changes in Brownian relaxation due to viscosity changes in apoptotic cells. There are only minor changes in relaxation time in cells labeled with Néelian SPIOs (VivoTrax). These data show great promise for MPI cell tracking using Brownian SPIOs to monitor therapeutic cell viability.

## IV. Conclusion

Nanoscale viscosity is challenging to measure *in vivo*. We have demonstrated that Brownian MPI relaxation is a

new and unexplored tool for measuring viscosity changes during cell death. No other cell tracking tool (MRI, CT, X-ray or nuclear medicine) offers this unique cell viability sensing ability. In the future, we plan to exploit Brownian relaxation contrast to allow for distinguishing bound SPIOs (which will have restricted rotation) from unbound SPIOs in an imaging format. This remains an open challenge for medical imaging.

#### Acknowledgments

We gratefully acknowledge support from NIH grants R01s EB019458, EB024578, EB029822 and R44: EB029877, UC TRDRP grant 26IP-0049, M. Cook Chair, Bakar Fellowship, the Siebel fellowship, the UC Discovery Award, the Craven Fellowship from UC Berkeley Bioengineering, NSERC fellowship, as well as the NIH-T32 training and NSF fellowships.

### Author's statement

Conflict of interest: Dr. Conolly is a co-founder of a startup company that manufactures and sells preclinical MPI scanners. Part of this work was presented at the world molecular imaging congress.

# References

- <span id="page-2-1"></span>[1] B. Zheng, M. P. von See, E. Yu, B. Gunel, K. Lu, T. Vazin, D. V. Schaffer, P. W. Goodwill, and S. M. Conolly. Quantitative Magnetic Particle Imaging Monitors the Transplantation, Biodistribution, and Clearance of Stem Cells In Vivo. *Theranostics*, 6(3):291–301, 2016.
- <span id="page-2-0"></span>[2] M. J. Gorbet and A. Ranjan. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. *Pharmacol Ther*, 207:107456, 2020.
- <span id="page-2-2"></span>[3] B. Zheng, T. Vazin, P. W. Goodwill, A. Conway, A. Verma, E. U. Saritas, D. Schaffer, and S. M. Conolly. Magnetic Particle Imaging tracks the long-term fate of in vivo neural cell implants with high image contrast. *Sci Rep*, 5:14055, 2015.
- [4] X. Y. Zhou, K. E. Jeffris, E. Y. Yu, B. Zheng, P. W. Goodwill, P. Nahid, and S. M. Conolly. First in vivo magnetic particle imaging of lung perfusion in rats. *Phys Med Biol*, 62(9):3510–3522, 2017.
- [5] E. Y. Yu, P. Chandrasekharan, R. Berzon, Z. W. Tay, X. Y. Zhou, A. P. Khandhar, R. M. Ferguson, S. J. Kemp, B. Zheng, P. W. Goodwill, M. F. Wendland, K. M. Krishnan, S. Behr, J. Carter, and S. M. Conolly. Magnetic Particle Imaging for Highly Sensitive, Quantitative, and Safe in Vivo Gut Bleed Detection in a Murine Model. *ACS Nano*, 11(12):12067–12076, 2017.
- [6] B. Zheng, E. Yu, R. Orendorff, K. Lu, J. J. Konkle, Z. W. Tay, D. Hensley, X. Y. Zhou, P. Chandrasekharan, E. U. Saritas, P. W. Goodwill, J. D. Hazle, and S. M. Conolly. Seeing SPIOs Directly In Vivo with Magnetic Particle Imaging. *Mol Imaging Biol*, 19(3):385–390, 2017.
- [7] X. Y. Zhou, Z. W. Tay, P. Chandrasekharan, E. Y. Yu, D. W. Hensley, R. Orendorff, K. E. Jeffris, D. Mai, B. Zheng, P. W. Goodwill, and S. M. Conolly. Magnetic particle imaging for radiation-free, sensitive and high-contrast vascular imaging and cell tracking. *Curr Opin Chem Biol*, 45:131–138, 2018.
- <span id="page-2-3"></span>[8] Z. W. Tay, P. Chandrasekharan, X. Y. Zhou, E. Yu, B. Zheng, and S. Conolly. In vivo tracking and quantification of inhaled aerosol using magnetic particle imaging towards inhaled therapeutic monitoring. *Theranostics*, 8(13):3676–3687, 2018.
- <span id="page-2-4"></span>[9] P. Chandrasekharan, Z. W. Tay, D. Hensley, X. Y. Zhou, B. K. Fung, C. Colson, Y. Lu, B. D. Fellows, Q. Huynh, C. Saayujya, E. Yu, R. Orendorff, B. Zheng, P. Goodwill, C. Rinaldi, and S. Conolly. Using magnetic particle imaging systems to localize and guide magnetic hyperthermia treatment: tracers, hardware, and future medical applications. *Theranostics*, 10(7):2965–2981, 2020.
- <span id="page-2-5"></span>[10] W. T. Coffey, Y. P. Kalmykov, and J. T. Waldron, The Langevin Equation, 2nd. WORLD SCIENTIFIC, 2004, doi[:10.1142](https://dx.doi.org/10.1142/5343)/5343.
- <span id="page-2-6"></span>[11] C. Saayujya, K. H. Yeo, Q. Huynh, I. Rodrigo, B. Fellows, P. Chandrasekharan, and S. Conolly, Viscosity measurements using brownian superparamagnetic iron oxide nanoparticles, in *World Molecular Imaging Congress 2022*, WMIS, 2022.
- <span id="page-2-7"></span>[12] P. Chandrasekharan, C. Colson, K. Fung, Q. Huynh, C. Sayyujya, B. Fellows, Y. Lu, Z. W. Tay, and S. Conolly, Monitoring outcome of hyperthermia treatment by measuring relaxation induced blurring with magnetic particle spectroscopy, in *2020 World Molecular Imaging Congress (WMIC 2020)*.
- <span id="page-2-8"></span>[13] Z. W. Tay, P. W. Goodwill, D. W. Hensley, L. A. Taylor, B. Zheng, and S. M. Conolly. A High-Throughput, Arbitrary-Waveform, MPI Spectrometer and Relaxometer for Comprehensive Magnetic Particle Optimization and Characterization. *Sci Rep*, 6:34180, 2016.